MedPath

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Completed
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Registration Number
NCT02495974
Lead Sponsor
Astellas Pharma Europe Ltd.
Brief Summary

The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined as the time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
1763
Inclusion Criteria
  • Men with mCRPC who have been prescribed enzalutamide as part of standard clinical practice
  • Germany only: Enzalutamide will be prescribed according to the current SmPC (Summary of Product Characteristics)
Exclusion Criteria
  • Patients with the following will be excluded from study participation in France only:

    • Patients who have previously been treated with abiraterone acetate (Zytiga®) after docetaxel chemotherapy.
    • Patients who have previously been treated with cabazitaxel (Jevtana®)
    • Patients who have previously been treated with Xtandi®
    • Patients taking part in an interventional clinical trial

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with mCRPC prescribed enzalutamideenzalutamideOral
Primary Outcome Measures
NameTimeMethod
Time to treatment failure (TTF)up to 18 months

Time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.

Secondary Outcome Measures
NameTimeMethod
Time to prostate specific antigen (PSA) progressionup to 18 months

Time from initiation of enzalutamide to the date of PSA progression. PSA progression is defined as a PSA rise of greater than or equal to 25% and an absolute increase of greater than or equal to 2 ng/mL.

PSA responseup to 18 months
Time to disease progressionup to 18 months

Time from initiation of enzalutamide to the date of radiographic progression, PSA progression or clinical progression according to the investigator's assessment.

Overall Survival (France only)up to 18 months

Time from initiation of enzalutamide to death or patient survival at the end of the study.

Treatment durationup to 18 months
Reason for initiation of treatment with enzalutamideup to 18 months
Reason for enzalutamide discontinuationup to 18 months
Subsequent anti-neoplastic therapy for mCRPCup to 18 months
Time to opiate useup to 18 months
Pain assessed by Brief Pain Inventory Short Form (BPI-SF)up to 18 months

The questionnaire is a patient self-rating scale assessing the level of pain, effect of the pain on activities of daily living, and analgesic use.

Quality of life of participants assessed using EQ-5D-5Lup to 18 months

EuroQol5 dimension 5 level health state utility index - 5L (EQ-5D-5L) is a standardized instrument for use as a measure of health outcome. It is designed for self-completion by respondents comprising the following dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

Quality of life of participants assessed using FACT-Pup to 18 months

Functional Assessment of Cancer Therapy - Prostate (FACT-P) is a self reported instrument designed to assess patient function in physical, social/family, emotional, and functional well-being and further assesses items for prostate-related symptoms.

Number of participants hospitalizedup to 18 months
Number of visits to health care professionalsup to 18 months
Safety assessed by reported adverse eventsup to 18 months
Safety assessed by modification of treatment with enzalutamide as a response to adverse eventsup to 18 months
Number of Deathsup to 18 months

Deaths defined as deaths due to any cause

Trial Locations

Locations (182)

Site BL32001

🇧🇪

Brussels, Belgium

Site AT43004

🇦🇹

Wien, Austria

Site BL32003

🇧🇪

Bonheiden, Antwerpen, Belgium

Site BL32004

🇧🇪

Brasschaat, Antwerpen, Belgium

Site BL32007

🇧🇪

Haine-Saint-Paul, Hainaut, Belgium

Site BL32008

🇧🇪

Aalst, Oost-Vlaanderen, Belgium

Site BL32011

🇧🇪

Bruxelles, Belgium

Site BL32012

🇧🇪

Hasselt, Belgium

Site BG35903

🇧🇬

Plovdiv, Bulgaria

Site BG35901

🇧🇬

Sofia, Bulgaria

Site FR33025

🇫🇷

Vannes, Bretagne, France

Site FR33033

🇫🇷

Evreux, Eure, France

Site FR33002

🇫🇷

Quimper, Finistère, France

Site FR33049

🇫🇷

Gap, Hautes-Alpes, France

Site FR33016

🇫🇷

Saint-Priest-en-Jarez, Loire, France

Site FR33065

🇫🇷

Agen, Lot-et-Garonne, France

Site FR33020

🇫🇷

Tours, Indre-et-Loire, France

Site IR35302

🇮🇪

Dublin, Ireland

Site IR35305

🇮🇪

Dublin, Ireland

Site GC30006

🇬🇷

Ioannina, Greece

Site HU36001

🇭🇺

Budapest, Hungary

Site GB44005

🇬🇧

Worcester, Worcestershire, United Kingdom

Site AT43001

🇦🇹

Bregenz, Austria

Site AT43005

🇦🇹

Innsbruck, Austria

Site AT43006

🇦🇹

Linz, Austria

Site BL32010

🇧🇪

Sint-Niklaas, Oost-Vlaanderen, Belgium

Site BL32013

🇧🇪

Leuven, Vlaams Brabant, Belgium

Site BL32009

🇧🇪

Gent, Oost-Vlaanderen, Belgium

Site BL32005

🇧🇪

Kortrijk, West-Vlaanderen, Belgium

Site CZ42001

🇨🇿

Praha, Czechia

Site CZ42004

🇨🇿

Brno, Czechia

Site CZ42007

🇨🇿

Jihlava, Czechia

Site CZ42006

🇨🇿

Praha, Czechia

Site CZ42003

🇨🇿

Novy Jicin, Czechia

Site FR33015

🇫🇷

Colmar, Alsace, France

Site FR33017

🇫🇷

Bordeaux, Aquitaine, France

Site FR33003

🇫🇷

Strasbourg, Alsace, France

Site FR33051

🇫🇷

Bordeaux, Aquitaine, France

Site FR33022

🇫🇷

Clermont Ferrand, Auvergne, France

Site FR33018

🇫🇷

Bordeaux, Aquitaine, France

Site FR33069

🇫🇷

Saint-Martin-Boulogne, Boulogne-sur-Mer, France

Site FR33026

🇫🇷

Brest Cedex 2, Bretagne, France

Site FR33043

🇫🇷

Sens, Bourgogne, France

Site FR33004

🇫🇷

Saint Grégoire, Bretagne, France

Site FR33062

🇫🇷

Longjumeau, Essonne, France

Site FR33040

🇫🇷

Toulouse, Haute-Garonne, France

Site FR33042

🇫🇷

Suresnes, Hauts-de-Seine, France

Site FR33060

🇫🇷

Grenoble, Isère, France

Site FR33066

🇫🇷

Orléans, Loiret, France

Site FR33050

🇫🇷

Bézier, Languedoc-Roussillon, France

Site FR33061

🇫🇷

Vandœuvre-lès-Nancy, Lorraine, France

Site FR33007

🇫🇷

Nancy, Meurthe-et-Moselle, France

Site FR33059

🇫🇷

Albi, Midi-Pyrénées, France

Site FR33021

🇫🇷

Coudekerque-Branche Cedex, Nord, France

Site FR33039

🇫🇷

Lille, Nord-Pas-de-Calais, France

Site FR33063

🇫🇷

Beauvais, Oise, France

Site IT39010

🇮🇹

Lecco, Lombardia, Italy

Site FR33006

🇫🇷

Aix en Provence, Bouches-du-Rhône, France

Site FR33041

🇫🇷

Marseille, Bouches-du-Rhône, France

Site FR33027

🇫🇷

Marseille, Bouches-du-Rhône, France

Site FR33019

🇫🇷

Angers, Maine-et-Loire, France

Site FR33067

🇫🇷

Dijon, Côte-d'Or, France

Site DK45003

🇩🇰

Aalborg, Denmark

Site DK45004

🇩🇰

Aarhus, Denmark

Site DK45002

🇩🇰

Copenhagen, Denmark

Site DK45001

🇩🇰

Herlev, Denmark

Site FR33010

🇫🇷

Reims Cedex, Champagne-Ardenne, France

Site FR33001

🇫🇷

Avignon Cedex 9, Vaucluse, France

Site GC30001

🇬🇷

Kifisia, Attiki, Greece

Site GC30004

🇬🇷

Ioannina, Greece

Site GC30008

🇬🇷

Thessaloniki, Greece

Site GC30002

🇬🇷

Thessaloniki, Greece

Site HU36003

🇭🇺

Szombathely, Hungary

Site FR33070

🇫🇷

Amiens, Picardie, France

Site FR33038

🇫🇷

La Chaussée-Saint-Victor, France

Site FR33028

🇫🇷

Clermont Ferrand Cedex 1, Puy-de-Dôme, France

Site FR33058

🇫🇷

Chalon-Sus-Saone, Saône-et-Loire, France

Site FR33008

🇫🇷

Amiens, Somme, France

Site FR33037

🇫🇷

Saint Mandé, Val-de-Marne, France

Site FR33012

🇫🇷

Lyon Cedex 9, Rhône, France

Site FR33030

🇫🇷

Lyon, Rhône, France

Site FR33032

🇫🇷

Amiens, Somme, France

Site FR33014

🇫🇷

Créteil, Val-de-Marne, France

Site FR33011

🇫🇷

Toulon, Var, France

Site FR33044

🇫🇷

Saint Quentin Cedex, Picardie, France

Site FR33009

🇫🇷

Valence, Rhône-Alpes, France

Site FR33054

🇫🇷

Hyères, France

Site FR33035

🇫🇷

Bayonne, Pyrénées-Atlantiques, France

Site FR33046

🇫🇷

Arras, France

Site FR33034

🇫🇷

Paris, France

Site FR33057

🇫🇷

Paris, France

Site FR33029

🇫🇷

Paris, France

Site DE49001

🇩🇪

Nürtingen, Baden-Württemberg, Germany

Site SV38501

🇸🇮

Ljubljana, Slovenia

Site GC30007

🇬🇷

Athens, Greece

Site IT39005

🇮🇹

Bari, Italy

Site FR33064

🇫🇷

Paris, France

Site DE49016

🇩🇪

Wiesbaden, Hessen, Germany

Site DE49005

🇩🇪

Köln, Germany

Site DE49012

🇩🇪

Chemnitz, Sachsen, Germany

Site GC30013

🇬🇷

Athens, Greece

Site GC30005

🇬🇷

Athens, Greece

Site GC30010

🇬🇷

Athens, Greece

Site GC30003

🇬🇷

Athens, Greece

Site DE49010

🇩🇪

Würselen, Germany

Site DE49015

🇩🇪

Kiel, Schleswig-Holstein, Germany

Site DE49003

🇩🇪

Lüneburg, Niedersachsen, Germany

Site DE49011

🇩🇪

Soltau, Niedersachsen, Germany

Site DE49013

🇩🇪

Bonn, Nordrhein-Westfalen, Germany

Site DE49009

🇩🇪

Bernburg, Sachsen-Anhalt, Germany

Site DE49006

🇩🇪

Rostock, Germany

Site DE49014

🇩🇪

Wuppertal, Germany

Site GC30012

🇬🇷

Larissa, Greece

Site GC30011

🇬🇷

Thessaloniki, Greece

Site GB44012

🇬🇧

Torquay, Devon, United Kingdom

Site HU36006

🇭🇺

Debrecen, Hajdú-Bihar, Hungary

Site HU36005

🇭🇺

Szeged, Hungary

Site IR35304

🇮🇪

Dublin, Ireland

Site IT39002

🇮🇹

Aviano, Pordenone, Italy

Site IT39011

🇮🇹

Mirano, Venezia, Italy

Site IT39008

🇮🇹

Padova, Italy

Site HU36002

🇭🇺

Budapest, Hungary

Site IR35306

🇮🇪

Dublin, Ireland

Site IT39001

🇮🇹

Meldola, Forlì, Italy

Site IT39009

🇮🇹

Rozzano, Milano, Italy

Site IT39013

🇮🇹

Candiolo, Torino, Italy

Site IT39012

🇮🇹

Catania, Italy

Site IT39006

🇮🇹

Firenze, Italy

Site IT39004

🇮🇹

Milano, Italy

Site IT39017

🇮🇹

Milano, Italy

Site IT39003

🇮🇹

Modena, Italy

Site IT39007

🇮🇹

Napoli, Italy

Site IT39018

🇮🇹

Novara, Italy

Site NL31007

🇳🇱

Breda, Netherlands

Site NL31008

🇳🇱

Helmond, Netherlands

Site PT35101

🇵🇹

Porto, Portugal

Site GB44007

🇬🇧

Treliske, Truro, United Kingdom

Site ES34010

🇪🇸

Reus, Cataluña, Spain

Site ES34017

🇪🇸

Vigo, Galicia, Spain

Site ES34008

🇪🇸

Guadalajara, Castilla La Mancha, Spain

Site ES34007

🇪🇸

Zaragoza, Aragón, Spain

Site NL31005

🇳🇱

Doetinchem, Netherlands

Site NL31010

🇳🇱

Nieuwegein, Netherlands

Site GB44001

🇬🇧

Aberdeen, Aberdeenshire, United Kingdom

Site GB44025

🇬🇧

Poole, Dorset, United Kingdom

Site GB44002

🇬🇧

Lincoln, Lincolnshire, United Kingdom

Site GB44008

🇬🇧

Berkshire, Slough, United Kingdom

Site GB44013

🇬🇧

Weston-super-Mare, Somerset, United Kingdom

Site IT39015

🇮🇹

Palermo, Italy

Site IT39016

🇮🇹

Reggio Emilia, Italy

Site GB44020

🇬🇧

Guildford, United Kingdom

Site GB44017

🇬🇧

Newcastle upon Tyne, United Kingdom

Site GB44006

🇬🇧

Reading, United Kingdom

Site GB44003

🇬🇧

London, United Kingdom

Site ES34016

🇪🇸

Lugo, Galicia, Spain

Site ES34004

🇪🇸

Badajoz, Extremadura, Spain

Site ES34012

🇪🇸

Zaragoza, Aragón, Spain

Site NL31011

🇳🇱

Zwolle, Netherlands

Site IT39014

🇮🇹

Pisa, Italy

Site ES34011

🇪🇸

Lleida, Cataluña, Spain

Site ES34013

🇪🇸

Barcelona, Cataluña, Spain

Site ES34006

🇪🇸

Cáceres, Extremadura, Spain

Site NL31006

🇳🇱

Arnhem, Netherlands

Site NL31003

🇳🇱

Den Haag, Netherlands

Site NL31004

🇳🇱

Hoofddorp, Netherlands

Site GB44011

🇬🇧

Preston, Lancashire, United Kingdom

Site ES34003

🇪🇸

Orense, Galicia, Spain

Site ES34005

🇪🇸

A Coruña, Galicia, Spain

Site NL31001

🇳🇱

Hilversum, Netherlands

Site GB44004

🇬🇧

Boston, Lincolnshire, United Kingdom

Site GB44015

🇬🇧

Norfolk, United Kingdom

Site ES34001

🇪🇸

Santiago de Compostela, Galicia, Spain

Site GB44026

🇬🇧

Blackburn, Lancashire, United Kingdom

Site ES34009

🇪🇸

Toledo, Castilla La Mancha, Spain

Site GB44009

🇬🇧

Swindon, Wiltshire, United Kingdom

Site GB44023

🇬🇧

Birmingham, United Kingdom

Site GB44010

🇬🇧

Brighton, United Kingdom

Site GB44016

🇬🇧

Derby, United Kingdom

Site GB44022

🇬🇧

Inverness-shire, United Kingdom

Site GB44024

🇬🇧

Leicester, United Kingdom

Site GB44014

🇬🇧

Taunton, United Kingdom

Site GB44018

🇬🇧

Wolverhampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath